IMUGENE LIMITED (ASX: IMU)
Health care · News and insights
Price unavailable
Latest IMU announcements
Announcement Insights
Imugene Advances Azer-Cel Toward Later-Stage Testing as Early Combination Responses Emerge
Imugene’s azer-cel program has reported encouraging but early Phase 1b response data alongside a clearer development timetable. The company reported a 77% response rate across Phase 1b patients and 86% in the BTK-inhibitor combination cohort, while cautioning that the combination results are early; it expects to complete enrolment in the second quarter of 2027, meet the FDA in mid-2027 and target a registrational study in the second half of 2027 or 2028. A roughly $2 million FY2026 R&D refund is intended to support recruitment, and the planned next steps remain subject to the trial’s progress and regulatory discussions.}
Updated 16 Nov 2026, 09:19 AM Sydney time
Sources
Imugene Receives $2.1M R&D Tax RefundAGM PresentationResults of 2026 Annual General MeetingDirector Resignation and Committee ChangesImugene selected for Poster Presentation at 2026 ASH MeetingPositive amendments to Convertible NotesQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-16 · Health care
IMU: $0.035 -2.78% · MC: $20M
Imugene has received an approximately $2 million R&D tax refund for FY2026, which it says will assist patient recruitment in the BTK-inhibitor combination cohort of its Phase 1b azer-cel study.
Updated 2026-11-16 09:09
Sources
Imugene Receives $2.1M R&D Tax RefundComments
2026-11-11 · Health care
IMU: $0.034 -5.56% · MC: $20M
At its AGM, Imugene said azer-cel had a 77% response rate across Phase 1b patients, with early BTK-inhibitor combination data showing an 86% response rate; the company cautioned that the combination results are early. It expects to complete Phase 1b enrolment in the second quarter of 2027, plans an FDA meeting in mid-2027 to discuss the registration pathway, and is targeting a registrational study in the second half of 2027 or 2028, while out-licensing discussions are underway. The AGM also approved all resolutions, and non-executive director Lesley Russell resigned, prompting committee changes.
Updated 2026-11-11 14:04
Sources
AGM PresentationResults of 2026 Annual General MeetingDirector Resignation and Committee ChangesComments
2026-11-05 · Health care
IMU: $0.035 +16.67% · MC: $20M
Imugene said its azer-cel study of treatment alongside BTK inhibitors in relapsed or refractory B-cell cancers has been selected for a poster presentation at the American Society of Hematology’s annual meeting in December. The company plans to present emerging Phase 1b data; shares rose around 13% on the day, alongside the update.
Updated 2026-11-05 15:33
Sources
Imugene selected for Poster Presentation at 2026 ASH MeetingComments
2026-11-03 · Health care
IMU: $0.033 -2.94% · MC: $20M
Imugene has amended terms on its convertible notes with CVI, giving it a new option to redeem some or all of the notes before maturity, but only with CVI’s prior written consent and subject to agreed conditions. The company says the change is intended to improve near-term cash-flow flexibility; the notes’ face values and warrant terms are unchanged.
Updated 2026-11-03 10:01
Sources
Positive amendments to Convertible NotesComments
2026-10-30 · Health care
IMU: $0.035 -7.89% · MC: $20M
Imugene reported responses in six of seven evaluable patients in its azer-cel BTKi combination cohort, an 86% response rate, while the CAR T-naïve cohort recorded an 81% response rate after quarter end. Quarterly net operating cash outflow fell 19% from the prior quarter, with staff costs down 51%; cash stood at approximately $5 million before an expected R&D tax incentive refund. The results are early and based on small patient groups, with further follow-up needed to assess response durability.
Updated 2026-10-30 09:46
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments